Results 11 to 20 of about 84,964 (303)

A comparative study between lateral internal anal sphincterotomy and botulinum toxin injection in the treatment of chronic anal fissure

open access: yesZanco Journal of Medical Sciences, 2021
Background and objective: The gold standard for the treatment of chronic anal fissure is lateral internal sphincterotomy. Botulinum toxin injection provides temporary alleviation of sphincter spasm and allows the fissure to heal.
Abdulqadir M. Zngana, Bawan Hiwa
doaj   +1 more source

Prolonged Antipruritic Effect of Botulinum Toxin Type A on Cowhage-induced Itch: A Randomized, Single-blind, Placebo-controlled Trial

open access: yesActa Dermato-Venereologica, 2023
Botulinum toxin type A (Botox®) is thought to have antipruritic effects through inhibition of pruritic factors, including acetylcholine, substance P, and glutamate. The aim of this randomized, single-blind, placebo-controlled trial was to test the effect
Leigh A. Nattkemper   +7 more
doaj   +1 more source

Current status and future directions of botulinum neurotoxins for targeting pain processing. [PDF]

open access: yes, 2015
Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into peripheral tissues such as skin, muscles, and joints, alter nociceptive processing otherwise initiated by inflammation or nerve injury in animal models and humans.
Pellett, Sabine   +2 more
core   +5 more sources

The Effects of Botulinum Toxin (BTXA) Dermal Injections on Facial Wrinkle Lines. [PDF]

open access: yesArchives of Aesthetic Plastic Surgery, 2013
Facial rejuvenation using Botulinum toxin A is one of the most popular aesthetic procedures. Many cosmetic applications of Botulinum toxin A are under evaluation.
Sung Chul Park   +3 more
doaj   +1 more source

Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan

open access: yeseNeurologicalSci, 2021
To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient ...
Ryuji Kaji   +3 more
doaj   +1 more source

Botulinum toxin

open access: yesIndian Journal of Dermatology, 2010
Botulinum toxin, one of the most poisonous biological substances known, is a neurotoxin produced by the bacterium Clostridium botulinum. C. botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C(1), C(2), D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal ...
Nigam P, Nigam Anjana
openaire   +3 more sources

Botulinum toxin for the treatment of lower limb cramp pain in patients with Amyotrophic Lateral Sclerosis [PDF]

open access: yes, 2020
Background: Muscle cramps and pain associated with them can be seen in patients with amyotrophic lateral sclerosis (ALS) and are known to reduce the quality of life. Pharmacological treatment may not benefit all patients in treating these cramps.
Govindarajan, Raghav   +2 more
core   +2 more sources

The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease

open access: yesНеврология, нейропсихиатрия, психосоматика, 2017
The review presents the data of recent studies dealing with cognitive impairments (CI) in patients with Parkinson's disease (PD) and gives their characteristics and epidemiology, the specific features of the pathogenesis and clinical manifestations, as ...
G. N. Akhmadeeva   +3 more
doaj   +1 more source

Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome [PDF]

open access: yes, 2011
Objective: The aim of the study was a prospective assessment of patient-reported side effects in an open-label study after intradetrusor botulinum toxin injections for idiopathic overactive bladder (OAB). Patients and Methods: Botulinum toxin A injection
Alexander Buchner   +20 more
core   +1 more source

Clinical Relevance of Botulinum Toxin Immunogenicity [PDF]

open access: yes, 2012
Botulinum toxin type A is a 150 kD protein produced by Clostridium botulinum, which exists in a complex with up to six additional proteins. The ability of botulinum toxin to inhibit acetylcholine release at the neuromuscular junction has been exploited ...
Reiner Benecke
core   +1 more source

Home - About - Disclaimer - Privacy